Abstracts Archive - Page 2365 of 2425 - ACR Meeting Abstracts

Abstract Number: 872 • 2012 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 and Eotaxin Are Associated with Parameters of Cardiac Dysfunction in Juvenile Dermatomyositis
Thomas Schwartz¹, Ivar Sjaastad², Berit Flatø³, Maria Vistnes¹, Geir Christensen¹ and Helga Sanner³, ¹Institute for Experimental Medical Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, ²Institute for Clinical Medicine, University of Oslo, Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
Background/Purpose : Juvenile dermatomyositis (JDM) is a vasculopathic disease affecting not only skeletal muscle and skin, but other organs as well. Previously we have shown…
Abstract Number: 833 • 2012 ACR/ARHP Annual Meeting
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study of Intravenous Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis On Methotrexate: Safety, Pharmacokinetics and Efficacy
Edward Bernton¹, Eduard Krantz² and William Gannon Jr.³, ¹Protalex Inc., Summit, NJ, ²Parexel Clinical Pharmacology, Bloemfontein, South Africa, ³Capital City Technical Consulting, Inc., Washington, DC
Background/Purpose: PRTX-100 is highly-purified GMP staphylococcal protein A (SpA) that binds with extremely high affinity to the Vh antibody framework region of Clade Vh3 immunoglobulins. …
Abstract Number: 834 • 2012 ACR/ARHP Annual Meeting
Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Significantly Reduces Tumour-Necrosis-Factor-Alpha and Demonstrates Efficacy in Patients with Active Rheumatoid Arthritis: A Proof-of-Concept, Double-Blind, Randomised Trial
Anita Kåss¹, Øystein T. Førre², Morten Fagerland³, Hans Christian Gulseth⁴, Peter Torjesen⁵ and Ivana Hollan⁶, ¹University of Oslo, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Biostatistics, Oslo University Hospital, Oslo, Norway, ⁴Rheumatology, Betanien Hospital, Skien, Norway, ⁵Department of Endocrinology, Oslo University Hospital, Oslo, Norway, ⁶Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and treatment options can be improved. Gonadotropin-releasing hormone (GnRH) stimulates immune responses (1) and therefore might…
Abstract Number: 835 • 2012 ACR/ARHP Annual Meeting
Low Doses of Ocaratuzumab, a Fc- and Fab-Engineered Anti-CD20 Antibody, Result in Rapid and Sustained Depletion of Circulating B-Cells in Rheumatoid Arthritis Patients
Adrienne O'Reilly, Tracy Davis and Vinay Jain, Mentrik Biotech, Dallas, TX
Background/Purpose: B-cell depletion provides therapeutic benefits for patients with rheumatoid arthritis (RA). Ocaratuzumab, previously known as AME-133v, is a Fc- and Fab-engineered, humanized, anti-CD20…
Abstract Number: 836 • 2012 ACR/ARHP Annual Meeting
Clinical Responses and Patient Reported Outcomes to NNC0109-0012 (anti-IL-20 mAb) in Rheumatoid Arthritis (RA) Patients Following 12-Weeks Dosing and 13 Weeks Follow up: Results From a Phase 2a Trial
Ladislav ŠEnolt¹, Marie Göthberg², Xavier Valencia³ and Eva Dokoupilova⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Biostatistics, Novo Nordisk, A/S, Soeborg, Denmark, ³Clinical Medical and Regulatory Affairs, Novo Nordisk, Inc., Princeton, NJ, ⁴Medical Plus s.r.o, Uherske Hradiste, Czech Republic
Background/Purpose: NNC0109-0012 (anti-IL-20 mAb) is a novel human monoclonal IgG4 antibody which binds to and neutralizes the activity of IL-20. Data from a phase 1…
Abstract Number: 837 • 2012 ACR/ARHP Annual Meeting
Response to MMF Therapy for Lupus Nephritis Is Independent of Genetic Variation of Inosine Monophosphate Dehydrogenase
Noa Schwartz¹, Tejaskumar Patel¹, Ellen M. Ginzler², Neil Solomons³, Jill P. Buyon⁴ and Robert M. Clancy¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ³Vifor Pharma, New York, NY, ⁴Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: The Aspreva Lupus Management Study (ALMS) demonstrated the efficacy of mycophenolate mofetil (MMF-a prodrug of MFA, mycophenolic acid) for both induction and maintenance of…
Abstract Number: 838 • 2012 ACR/ARHP Annual Meeting
Association of Urinary and Serum Soluble Fn14 Levels and TWEAK Levels with Lupus Nephritis Disease Activity
Irene Blanco¹, Ping Wu², Timothy S. Zheng³, Shawn Weng⁴, Jennifer S. Michaelson², Linda C. Burkly² and Chaim Putterman⁵, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Biogen Idec, Cambridge, MA, ³R&D - Rheumatology/Immunology, Biogen Idec Inc, Cambridge, MA, ⁴Biogen Idec, Inc., Cambridge, MA, ⁵Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: We have showed that the cytokine TWEAK is a biomarker for lupus nephritis (LN). However, soluble receptors for key immune pathways are also potential…
Abstract Number: 839 • 2012 ACR/ARHP Annual Meeting
Urinary Levels of High Mobility Group Box 1 Protein Are Elevated in Patients with Active Lupus Nephritis, and Correlate with Renal Histopathology
Irene Blanco¹, Neelakshi Jog², Chaim Putterman³, Iris Lee⁴ and Roberto Caricchio⁵, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Temple University, Philadelphia, PA, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Nephrology, Temple University, Philadelphia, PA, ⁵Medicine/Rheumatology, Temple University, Philadelphia, PA
Background/Purpose: High mobility group box 1 protein (HMGB-1) had been implicated in the pathogenesis of SLE and potentially lupus nephritis (LN). There is increased expression…
Abstract Number: 840 • 2012 ACR/ARHP Annual Meeting
Do Serum Hepcidin 25 Levels Predict SLE Renal or Non-Renal Flares?
Alexandra Friedman¹, Nicholas Young², Paul Jensen³, Xiaolin Zhang⁴, Wael N. Jarjour⁵, Brad H. Rovin⁴, Daniel Birmingham³, Lee Hebert³ and Stacy P. Ardoin⁶, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ³Medicine, Ohio State University Medical Center, Columbus, OH, ⁴Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ⁵Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose: Biomarkers are needed which can accurately predict systemic lupus erythematosus (SLE) flare, allowing tailoring of immunosuppressive therapy to minimize disease damage and medication toxicity.…
Abstract Number: 841 • 2012 ACR/ARHP Annual Meeting
Effect of Partial and Complete Proteinuria Recovery in Lupus Nephritis On Long Term Outcomes
Zahi Touma¹, Murray B. Urowitz², Dominique Ibanez² and D. D. Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The identification of partial proteinuria recovery (PPR) of ≥ 50% allows for the detection of an additional number of patients who improve their proteinuria…
Abstract Number: 842 • 2012 ACR/ARHP Annual Meeting
Partial and Complete Recovery From Proteinuria in Lupus Nephritis Patients Receiving Standard of Care Treatment
Zahi Touma¹, D. D. Gladman², Dominique Ibanez³ and Murray B. Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: In the majority of trials on lupus, partial proteinuria recovery (PPR) (≥ 50% decrease in the proteinuria level) is a component of the composite…
Abstract Number: 843 • 2012 ACR/ARHP Annual Meeting
Interferon Regulatory Factor 5 Associates with Systemic Lupus Erythematosus Through Two Distinct and Independent Effects
Erin Zoller¹, Leah C. Kottyan², Bahram Namjou¹, Samuel Vaughn¹, Miranda C. Marion³, Carl D. Langefeld⁴, Marta E. Alarcon-Riquelme⁵, Juan-Manuel Anaya⁶, Elizabeth E. Brown on behalf of PROFILE⁷, Sang-Cheol Bae⁸, Jeffrey C. Edberg⁹, Patrick M. Gaffney¹⁰, Diane L. Kamen¹¹, Robert P. Kimberly¹², Chaim O. Jacob¹³, Joan T. Merrill¹⁴, Kathy Moser Sivils¹⁵, Michelle Petri¹⁶, Rosalind Ramsey-Goldman¹⁷, John D. Reveille¹⁸, Anne M. Stevens¹⁹, Betty P. Tsao²⁰, Luis M. Vila²¹, Timothy J. Vyse²² and Kenneth M. Kaufman²³, ¹Division of Rheumatology and The Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, ⁴Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁶School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ¹²Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ¹⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁸Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ¹⁹Pediatrics, University of Washington, Seattle, WA, ²⁰Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA, ²¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²²Medical & Molecular Genetics, King's College London, London, United Kingdom, ²³1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH
Background/Purpose: Powerful evidence suggests that Systemic lupus erythematous (SLE or lupus) autoimmunity is mediated by disregulation of the IRF5-NFκB signaling pathway. The interferon regulatory factor 5…
Abstract Number: 844 • 2012 ACR/ARHP Annual Meeting
Toll-Like Receptor 9-Independent and Immune Complex-Independent Interferon-α Production by Neutrophils Upon Netosis in Response to Circulating Chromatin
Dennis Lindau¹, Julie Mussard², Armin Rabsteyn¹, Matthieu Ribon², Ina Kötter³, Annette Igney³, Gosse Adema⁴, Marie-Christophe Boissier⁵, Hans-Georg Rammensee¹ and Patrice Decker⁶, ¹Department of Immunology, University of Tübingen, Institute for Cell Biology, Tübingen, Germany, ²INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, ³Department of Internal Medicine II, Rheumatology Division, Tübingen, Germany, ⁴Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands, ⁵Avicenne Hospital, Rheumatology Department, Bobigny, France, ⁶EA4222, Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France
Background/Purpose: Chromatin (which is composed of DNA and histones) represents a major autoantigen in systemic lupus erythematosus (SLE). Interferon-α (IFN-α) plays an important role in…
Abstract Number: 845 • 2012 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Immune Complexes Upregulate the Expression of CD319 and CD229 On Plasmacytoid Dendritic Cells
Niklas Hagberg¹, Jakob Theorell², Gunnar V. Alm³, Maija-Leena Eloranta⁴, Yenan Bryceson² and Lars Rönnblom⁴, ¹Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ²Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden, ⁴Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden
Background/Purpose: Patients with SLE have an activated type I interferon (IFN) system due to an ongoing IFN-alpha synthesis by plasmacytoid dendritic cells (pDCs) stimulated by…
Abstract Number: 846 • 2012 ACR/ARHP Annual Meeting
Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele up-Regulates IL10 Expression
Daisuke Sakurai¹, Jian Zhao¹, Yun Deng¹, Jennifer A. Kelly², Kathy Moser Sivils², Kenneth M. Kaufman³, Elizabeth E. Brown on behalf of PROFILE⁴, Marta E. Alarcón-Riquelme on behalf of BIOLUPUS and GENLES network⁵, John B. Harley⁶, Sang-Cheol Bae⁷, Chaim O. Jacob⁸, Timothy J. Vyse⁹, Timothy B. Niewold¹⁰, Patrick M. Gaffney¹¹, Judith A. James², Robert P. Kimberly¹², Gary S. Gilkeson¹³, Diane L. Kamen¹⁴, Carl D. Langefeld¹⁵, Deh-Ming Chang¹⁶, Yeong Wook Song¹⁷, Weiling Chen¹, Jennifer M. Grossman¹, Bevra H. Hahn¹⁸ and Betty P. Tsao¹, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arthritis and Clinical Immunology, Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁷Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, ⁸Department of Medicine,, Keck School of Medicine, University of Southern California, Los Angeles, CA, ⁹Divisions of Genetics and Molecular Medicine and Immunology,, King's College London, London, United Kingdom, ¹⁰Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹³Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹⁴Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ¹⁵Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹⁶Headquarter, National Defense Medical Center, Taipei, ¹⁷Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ¹⁸Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose:The established association between IL10 and multiple autoimmune diseases including SLE and elevated levels of IL-10 in SLE patients correlating with disease activity led us to fine-map…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].